List of Excipients in Branded Drug DEXYCU

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
EyePoint Pharmaceuticals US Inc	DEXYCU	dexamethasone	71879-001	ACETYLTRIETHYL CITRATE
EyePoint Pharmaceuticals US Inc	DEXYCU	dexamethasone	71879-001	NITROGEN

Last updated: August 9, 2026

D­­EXYCU’s commercial value is tied to its delivery system, not to novel steroid pharmacology. The product uses dexamethasone 9% in a low-excipient, intraocular suspension designed for administration at the end of cataract surgery. The main opportunity is to improve manufacturing robustness, dose uniformity, handling, and reimbursement economics without changing the excipient architecture that supports ocular tolerability and sustained exposure.

DEXYCU Excipient Strategy, Patent Position, and Commercial Opportunities

What is DEXYCU and how does its formulation work?

DEXYCU is dexamethasone intraocular suspension 9%, an intracameral corticosteroid indicated for the treatment of postoperative inflammation after ocular surgery. The FDA approved DEXYCU in 2018. EyePoint Pharmaceuticals commercializes the product in the United States. [1,2]

Unlike conventional dexamethasone eye drops, DEXYCU is administered once by the surgeon at the conclusion of surgery. The formulation is designed to remain in the capsular bag and release dexamethasone over the postoperative period. The product is a suspension rather than a conventional aqueous solution, which allows a high drug load to be delivered in a small intraocular volume. [1]

The formulation strategy addresses four product requirements:

1. High local steroid concentration.
2. Sustained intraocular residence.
3. Sterile, single-use administration.
4. Low excipient burden appropriate for injection into the eye.

The FDA label identifies dexamethasone as the active ingredient and lists povidone, polysorbate 80, and water for injection as inactive ingredients. [1]

What excipients are used in DEXYCU?

The labeled excipients are:

Component	Formulation role	Commercial and technical relevance
Povidone	Suspending, viscosity-modifying, and wetting support	Influences particle settling, redispersion, and intraocular residence
Polysorbate 80	Surfactant and wetting agent	Helps control particle aggregation and improve suspension uniformity
Water for injection	Sterile vehicle	Supports parenteral manufacturing and ophthalmic tolerability
Dexamethasone	Active corticosteroid	Present at 9% concentration in the intraocular suspension

[1]

The public label does not assign a separate functional role to every excipient. In practice, the excipient system should be evaluated as an interacting suspension platform. Povidone and polysorbate 80 affect particle wetting, aggregation, sedimentation, redispersion, and syringeability. Changes in either material can alter critical quality attributes even if the nominal excipient concentration remains unchanged.

Why is the DEXYCU excipient system commercially important?

The formulation is commercially important because DEXYCU competes against low-cost topical corticosteroids while offering a different administration model. Its value proposition depends on eliminating or reducing postoperative steroid-drop administration by the patient.

A small excipient system can reduce several development and supply-chain risks:

• Fewer raw materials require qualification.
• The toxicological package is narrower.
• Analytical method development is more focused.
• Excipient-related regulatory questions are easier to manage.
• Supplier redundancy is more practical than for a complex lipid or polymer matrix.

The main tradeoff is that each excipient has a larger impact on product performance. A change in povidone grade, molecular-weight distribution, peroxide level, or solution viscosity can affect suspension stability. A change in polysorbate 80 source or degradation profile can affect particle wetting and aggregation.

For DEXYCU, excipient strategy is therefore a control strategy rather than a simple cost-reduction exercise.

What are the most important CMC risks for DEXYCU?

Particle size and dose uniformity

Dexamethasone particles must remain within a controlled particle-size distribution. Particle size affects sedimentation rate, redispersion, dissolution, ocular exposure, and the risk of visible or irritating particles.

The manufacturer must control:

• Mean and upper-tail particle size.
• Particle morphology.
• Agglomeration during storage.
• Suspension concentration after resuspension.
• Dose delivered through the administration device.

The high active concentration leaves limited room for suspension variability. A product that settles rapidly or does not redisperse consistently can create underdosing or overdosing risk.

Redispersion and handling

The product must be handled by surgical staff in a time-sensitive setting. The commercial product therefore requires predictable resuspension after storage and transport. The instruction to shake or otherwise resuspend the product is not a minor usability issue. It is linked directly to delivered dose.

A useful lifecycle-development target would be improved resuspension with fewer preparation steps, provided the change does not reduce chemical or physical stability.

Sterility and container closure

DEXYCU is supplied for single-use ophthalmic administration. Sterility assurance, particulate control, container-closure integrity, and compatibility with the delivery components are central quality requirements. The container and administration system can influence dose recovery, dead volume, and the amount of suspension retained in the syringe or needle.

Polysorbate degradation

Polysorbate 80 can undergo hydrolysis and oxidation. Degradation may generate subvisible particles, alter interfacial behavior, or affect active-particle stability. A commercial excipient program should therefore monitor:

• Peroxide and aldehyde levels.
• Fatty-acid composition.
• Hydrolysis products.
• Supplier-to-supplier variability.
• Compatibility with the drug substance and container closure.

Povidone variability

Povidone is not a single uniform material. Molecular-weight distribution, residual impurities, moisture, and viscosity can vary by grade and supplier. These variables can change suspension rheology and redispersion behavior. A dual-source strategy must use functional equivalence criteria, not only compendial identity testing.

What formulation patents protect DEXYCU?

The likely defensible value in DEXYCU is concentrated in the product’s formulation and delivery architecture. The active ingredient, dexamethasone, is an established corticosteroid and is not itself a new-molecule exclusivity asset.

Relevant intellectual-property categories include:

• High-concentration dexamethasone suspensions.
• Sustained-release intraocular delivery.
• Use of polymeric or viscous excipient systems.
• Administration into the capsular bag after cataract surgery.
• Particle-size and resuspension characteristics.
• Dose-delivery devices and surgical administration methods.
• Manufacturing processes for sterile suspension products.

EyePoint’s broader intellectual-property position derives from the Verisome delivery technology and related ocular drug-delivery patents. Public company filings identify intellectual property around sustained-release drug delivery and ophthalmic products, but patent scope and enforceability depend on the specific claims, prosecution history, terminal disclaimers, and Orange Book status. [2,3]

A competitor seeking to develop a DEXYCU substitute would not necessarily need to copy the same excipients. It could attempt a design-around using another suspending agent, surfactant, biodegradable polymer, depot matrix, or particle-engineering approach. The regulatory burden would remain significant because the substitute would need to demonstrate consistent intraocular safety, drug release, sterility, and clinical performance.

What is the Orange Book and regulatory status of DEXYCU?

DEXYCU is an FDA-approved drug product, not a biologic. Biosimilar pathways are therefore not relevant. The principal competitive pathway is an abbreviated new drug application, a 505(b)(2) application, or a new drug application for a differentiated intraocular steroid product.

The FDA label identifies DEXYCU as dexamethasone intraocular suspension 9% and provides the approved indication, dosage, administration, warnings, and inactive ingredients. [1]

Regulatory exclusivity and patent protection must be analyzed separately:

• FDA regulatory exclusivity depends on the approval pathway and statutory exclusivity period.
• Patent protection depends on issued claims and expiration dates.
• Orange Book listings can include drug-substance, drug-product, and method-of-use patents where applicable.
• A generic applicant may file a Paragraph IV certification against listed patents.
• A 30-month stay can arise if the patent holder brings suit within the statutory period after receiving a Paragraph IV notice.

The commercial significance of any DEXYCU patent depends on whether the claims cover the proposed generic’s formulation, method of use, or delivery system. A broad claim to a specific excipient combination could create a stronger barrier than a narrow claim limited to one concentration or administration step.

When does DEXYCU lose exclusivity?

DEXYCU does not face a conventional biosimilar event because it is a small-molecule ophthalmic drug. The key loss-of-exclusivity risks are:

1. Expiration or invalidation of formulation patents.
2. Expiration or non-enforceability of method-of-use patents.
3. A successful Paragraph IV challenge.
4. Approval of a 505(b)(2) product with a different delivery system.
5. Surgeon adoption of alternative sustained-release corticosteroid products.

The effective commercial exclusivity period may be shorter than the latest patent expiry if the patent estate has narrow claims, if a competitor develops a non-infringing formulation, or if surgeons accept a lower-cost topical regimen.

A generic DEXYCU product would face practical development challenges beyond patent clearance. It would need to reproduce or match critical attributes such as suspension uniformity, intraocular exposure, local tolerability, sterility, and administration performance. Those requirements can make a complex ophthalmic suspension more difficult to copy than an immediate-release oral tablet.

What generic entry risks exist for DEXYCU?

ANDA risk

An ANDA applicant could seek approval by demonstrating pharmaceutical equivalence and bioequivalence or through an FDA-accepted pathway for the product. The applicant would need to address the formulation’s suspension characteristics and delivery conditions.

The main ANDA vulnerabilities would be:

• Narrow or expired formulation claims.
• Claims limited to excipients that can be avoided.
• Weak method-of-use claims.
• Lack of patent claims covering critical particle or device attributes.
• A regulatory position that permits a substitute excipient system.

505(b)(2) risk

A 505(b)(2) applicant could seek approval for a modified intraocular dexamethasone product using the existing DEXYCU or other dexamethasone data as part of the evidentiary package. Possible differentiation routes include:

• A different concentration.
• A biodegradable depot.
• A prefilled delivery system.
• A combined steroid and antibiotic product.
• A lower-volume administration format.
• An alternative sustained-release particle system.

This pathway may create a more credible competitive threat than a direct generic if the competitor avoids key DEXYCU claims while offering improved handling or lower acquisition cost.

What commercial opportunities exist for excipient suppliers?

Qualified-source supply

Suppliers can create value by providing pharmaceutical-grade povidone and polysorbate 80 with tighter functional specifications, lower impurity profiles, and stronger lot-to-lot consistency. A dual-source package that preserves suspension performance could reduce supply risk for the manufacturer.

Low-peroxide polysorbate 80

Polysorbate 80 with controlled peroxide and aldehyde levels is commercially relevant for sterile ophthalmic suspensions. Supplier documentation should support oxidation monitoring, container compatibility, and stability-indicating analytical methods.

Functional-equivalent povidone

A supplier that can demonstrate equivalent molecular-weight distribution, viscosity behavior, particle-wetting performance, and impurity control may compete for a qualified alternate source. The opportunity is greater if the existing source has capacity constraints or if regional manufacturing redundancy is required.

Excipient-enabled lifecycle management

Excipient suppliers can support reformulation programs aimed at:

• Faster redispersion.
• Reduced shaking requirements.
• Better syringeability.
• Lower residual volume.
• Longer shelf life.
• Improved freeze-thaw and shipping stability.
• Compatibility with a prefilled device.

Any reformulation would require comparability work and potentially a supplemental FDA filing. The commercial upside would come from improved operating-room convenience, lower waste, or broader reimbursement acceptance.

How does DEXYCU compare with conventional dexamethasone drops?

Attribute	DEXYCU	Conventional dexamethasone drops
Administration	Single intraocular administration by surgeon	Repeated patient-administered dosing
Dosage form	High-concentration suspension	Topical ophthalmic solution or suspension
Excipient strategy	Low-excipient injectable suspension	Product-specific topical excipient system
Main value proposition	Reduced postoperative drop burden	Low acquisition cost and familiar use
Main technical risk	Dose uniformity, resuspension, intraocular delivery	Adherence and repeated dosing
Main commercial barrier	Reimbursement and surgeon adoption	Patient compliance
Generic competition	Complex sterile suspension or 505(b)(2) substitute	Established generic products

The competitive question is not whether DEXYCU contains a more potent steroid. It is whether the administration model produces enough clinical and operational value to justify its price relative to inexpensive topical alternatives.

What revenue exposure and market opportunities matter?

DEXYCU revenue is exposed to cataract-procedure volume, surgeon adoption, payer coverage, ambulatory surgery-center economics, and the availability of competing sustained-release products. The product can generate value in settings where postoperative adherence is poor, nursing support is limited, or surgeons prefer to control administration.

Growth opportunities include:

• Broader adoption in cataract surgery.
• Use in other ocular procedures if supported by clinical evidence and labeling.
• Combination products that reduce the number of postoperative medications.
• Preloaded or prefilled delivery systems.
• Licensing the delivery platform to other ophthalmic drug developers.
• Regional partnerships outside the United States.
• Contract manufacturing and formulation services for sustained-release ophthalmic products.

The strongest licensing opportunity is likely platform-based rather than excipient-based. Povidone and polysorbate 80 are widely available materials. The higher-value asset is the combination of drug loading, suspension behavior, intraocular residence, sterile presentation, and clinical administration workflow.

Key Takeaways

• DEXYCU is a dexamethasone 9% intraocular suspension approved for postoperative ocular inflammation.
• Its labeled inactive ingredients are povidone, polysorbate 80, and water for injection.
• The excipient system supports suspension stability, particle wetting, redispersion, and intraocular delivery.
• The principal CMC risks are particle-size control, dose uniformity, polysorbate degradation, povidone variability, sterility, and container compatibility.
• Patent value is more likely to reside in the delivery platform, formulation architecture, manufacturing process, and method of use than in dexamethasone itself.
• Generic and 505(b)(2) competition could avoid individual excipient claims through a different suspension or depot design.
• The strongest commercial opportunities are qualified-source excipients, low-peroxide polysorbate 80, functional-equivalent povidone, improved delivery systems, and licensing of sustained-release ophthalmic technology.
• DEXYCU’s market performance depends on whether reduced drop burden and controlled surgical administration justify the premium over generic dexamethasone drops.

FAQs About DEXYCU Excipients and Commercial Strategy

Does DEXYCU contain a preservative?

DEXYCU is a single-use intraocular product. Its labeled inactive ingredients are povidone, polysorbate 80, and water for injection. The product is not dependent on a multidose topical preservative system. [1]

Can polysorbate 80 be replaced in a DEXYCU-like product?

Potentially, but substitution would require demonstration of equivalent particle wetting, suspension stability, redispersion, chemical stability, ocular tolerability, and delivered dose. A replacement could also create new formulation patent and regulatory issues.

Is povidone responsible for sustained release?

Povidone can contribute to viscosity, wetting, and suspension behavior, but sustained intraocular exposure results from the overall suspension and delivery design. The label does not attribute a specific release mechanism solely to povidone. [1]

Could a competitor develop a preservative-free DEXYCU alternative?

A competitor could develop a sterile single-use alternative, but preservative status alone would not establish pharmaceutical equivalence. The product would still need to address particle engineering, intraocular exposure, administration, sterility, and patent clearance.

Is DEXYCU exposed to biosimilar competition?

No. DEXYCU is a small-molecule dexamethasone drug product. Competitive entry would occur through generic, 505(b)(2), or new ophthalmic product pathways rather than a biosimilar application.

References

1. U.S. Food and Drug Administration. (2018). DEXYCU (dexamethasone intraocular suspension) 9% prescribing information.
2. EyePoint Pharmaceuticals, Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.